eligibility_summary
Adults (≥18) with EGFR+ non‑keratinizing nasopharyngeal carcinoma (WHO II/III), recurrent/metastatic after prior PD‑1/PD‑L1 therapy, ≥1 measurable lesion, ECOG 0–1, survival ≥3 mo, adequate organ function. Exclude: hypersensitivity, recent strong CYP3A4/UGT1A1 agents, active HBV/HCV/HIV or serious infection, recent anticancer therapy, TCM or investigational Rx, recent major surgery or serious CV/embolic events, other active cancers, pregnant/nursing, uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm study in EGFR-positive recurrent/metastatic nasopharyngeal carcinoma after PD‑1/PD‑L1 therapy failure, evaluating liposomal irinotecan plus nituzumab. Liposomal irinotecan: a liposomal camptothecin prodrug (irinotecan→SN‑38), topoisomerase I inhibitor causing replication-associated DNA damage, liposomes improve tumor delivery and reduce systemic toxicity. Nituzumab: an anti‑EGFR monoclonal antibody that blocks ligand binding/EGFR signaling (RAS‑MAPK, PI3K‑AKT) and may trigger ADCC. Targets: EGFR-expressing tumor epithelial cells, DNA replication/topoisomerase I in proliferating tumor cells.